Why the study?
Does PI3K inhibition improve contractility in alpha1-adrenergically stimulated myocardium in isolated rabbit ventricular myocytes?
Does PI3K inhibition improve contractility in alpha1-adrenergically stimulated myocardium in isolated rabbit ventricular myocytes?
Inhibition of PI3K improves contractility in alpha1-adrenergically stimulated myocardium by increasing phospholamban phosphorylation and intracellular Ca2+ transients, suggesting a potential mechanism for treating acute heart failure.
PI3K inhibition may augment alpha1-adrenergic contractility in rabbit myocytes; hypothesis-generating, leaves open translation to clinical acute HF.
Recent studies have demonstrated that phosphoinositide 3-kinases (PI3Ks) play a fundamental role in regulating myocardial contractility. However, even though alpha1-adrenergic receptor stimulation is known to activate PI3Ks, the impact of this pathway on the inotropic effects of alpha1-stimulation is unclear. Isolated rabbit ventricular myocytes were preincubated with the PI3K inhibitor wortmannin (WM, 0.1 micromol/L). The alpha1 agonist phenylephrine (PE, 10 micromol/L) induced a significantly stronger increase in contractility in WM-treated versus control myocytes (Fractional shortening in percent of resting cell length: 6.14+/-0.33 percent; n=26 versus 4.85+/-0.33 percent; n=26, P less than 0.05). Furthermore, pretreatment with WM significantly increased the positive inotropic effect of PE in intact muscle strips from rabbit hearts. Mechanistically, we demonstrate that in WM-treated myocytes PE increased phospholamban (PLN) phosphorylation and intracellular Ca2+ transients to a significantly greater extent than in control myocytes. In summary, this is the first study to demonstrate that inhibition of PI3K by increasing PLN phosphorylation and Ca2+ transients significantly improves contractility in alpha1-adrenergically stimulated myocardium. This may have clinical implications for the treatment of decreased cardiac function in acute heart failure.
No takes yet. Share an insight, caveat, or question.
Claudius Jacobshagen (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: